Literature DB >> 16269598

Oncologic imaging in gynecologic malignancies.

Neeta Pandit-Taskar1.   

Abstract

(18)F-FDG PET imaging is underutilized in patients with gynecologic malignancies, and its role in current clinical practice has yet to be established. In cervical cancer, it has high sensitivity in detection of nodal disease. Its use is probably most suitable in patients with negative or ambiguous findings on other types of radiographic imaging. Data support its usefulness in asymptomatic cervical cancer patients with high tumor markers and negative conventional-imaging findings, although more data are needed to ascertain whether it has a positive impact on survival. Similarly, its role in monitoring response to therapies needs to be consolidated. In ovarian cancer, (18)F-FDG PET holds promise in evaluation of recurrent or residual disease when other radiographic data are uncertain. In endometrial cancer, there are encouraging, although limited, data supporting the use of (18)F-FDG PET in patients with recurrent disease. To reduce extensive lymph node dissection in patients and to decrease subsequent morbidity, investigators have advocated applying the sentinel node technique to patients with cervical, endometrial, or vulvar cancers. The overall results are encouraging for the use of LS in planning surgical procedures, although more data and larger planned studies are needed to establish clinical utility in the surgical management of patients with these malignancies.

Entities:  

Mesh:

Year:  2005        PMID: 16269598

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

1.  Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation.

Authors:  Katrien Vandecasteele; Wilfried De Neve; Werner De Gersem; Louke Delrue; Leen Paelinck; Amin Makar; Valérie Fonteyne; Carlos De Wagter; Geert Villeirs; Gert De Meerleer
Journal:  Strahlenther Onkol       Date:  2009-12       Impact factor: 3.621

Review 2.  Potential therapeutic strategies for lymphatic metastasis.

Authors:  Bernadette M M Zwaans; Diane R Bielenberg
Journal:  Microvasc Res       Date:  2007-09-19       Impact factor: 3.514

Review 3.  Gynecologic pathology on multidetector CT: a pictorial review.

Authors:  Jennifer E Swart; Elliot K Fishman
Journal:  Emerg Radiol       Date:  2008-05-21

Review 4.  Staging of carcinoma of the uterine cervix and endometrium.

Authors:  Takashi Koyama; Ken Tamai; Kaori Togashi
Journal:  Eur Radiol       Date:  2007-01-12       Impact factor: 7.034

5.  Potential role of a hybrid intraoperative probe based on OCT and positron detection for ovarian cancer detection and characterization.

Authors:  Yi Yang; Nrusingh C Biswal; Tianheng Wang; Patrick D Kumavor; Mozafareddin Karimeddini; John Vento; Melinda Sanders; Molly Brewer; Quing Zhu
Journal:  Biomed Opt Express       Date:  2011-06-13       Impact factor: 3.732

Review 6.  Diagnostic accuracy of preoperative tests for lymph node status in endometrial cancer: a systematic review.

Authors:  H M P Pelikan; J W Trum; F C H Bakers; R G H Beets-Tan; L J M Smits; R F P M Kruitwagen
Journal:  Cancer Imaging       Date:  2013-07-22       Impact factor: 3.909

7.  3D texture analysis for classification of second harmonic generation images of human ovarian cancer.

Authors:  Bruce Wen; Kirby R Campbell; Karissa Tilbury; Oleg Nadiarnykh; Molly A Brewer; Manish Patankar; Vikas Singh; Kevin W Eliceiri; Paul J Campagnola
Journal:  Sci Rep       Date:  2016-10-21       Impact factor: 4.379

8.  Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16alpha-18F-fluoro-17beta-estradiol PET.

Authors:  Yoshio Yoshida; Tetsuji Kurokawa; Tetuya Tsujikawa; Hidehiko Okazawa; Fumikazu Kotsuji
Journal:  J Ovarian Res       Date:  2009-06-16       Impact factor: 4.234

9.  Suppression of 18F-FDG signal in the bladder on small animal PET-CT.

Authors:  Lorena Cussó; Manuel Desco
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.